From hardy pigs to super-crops, gene
editing poses new EU dilemma
Send a link to a friend
[May 28, 2016]
By Ben Hirschler
LONDON (Reuters) - Heat-tolerant Angus
beef cattle designed for the tropics with white coats instead of black
or red. A button mushroom that doesn't turn brown. Pigs that don't fall
sick.
These are all ideas thrown up by gene editing, the new technology
taking the biomedical world by storm, and one which also promises a
revolution down on the farm.
It poses a thorny problem for European policymakers wary of new
molecular manipulation in agriculture after a quarter century of
conflict over genetically modified food.
In a research lab in Norwich, 100 miles northeast of London, Wendy
Harwood is making exact DNA tweaks in barley plants to produce
better-germinating grain, with higher yield and quality.
"We've never been able to go in and make such a precise change as we
can now with gene editing," said the John Innes Centre scientist.
"This gives you exactly the change you want without anything you
don't want."
Further to the south of England in Basingstoke, animal genetics firm
Genus has tapped the same "CRISPR-Cas9" technique to develop the
world's first pigs resistant to a devastating and common viral
disease, in a tie-up with U.S. researchers.
Agricultural scientists and companies worldwide are joining the gene
editing race, including seeds giant Monsanto, now the target of a
$62 billion takeover attempt by Germany's Bayer.
Rival DuPont, which is merging with Dow Chemical, hopes to have
CRISPR-edited corn and wheat on the market in five to 10 years.
Bright ideas from others include improved varieties of rice,
soybeans and tomatoes, as well as hornless cattle and the
heat-tolerant breed of Angus.
Using "molecular scissors" to cut DNA means scientists can edit
genomes more precisely and rapidly than ever before, and
agricultural products - which don't need the same clinical trials as
human drugs - could get to market relatively quickly.
U.S. GREEN LIGHT
Last month, a non-browning button mushroom became the first
CRISPR-edited organism to get a green light from the U.S. government
- and several crops developed with two older, less efficient editing
tools have already been waved through.
But whether such products will ever arrive on European farms is
another matter, since the European Commission has so far not made a
decision on how they will be regulated, leaving the new science in
limbo.
The EU executive had been due to decide by the end of 2015 whether
to class gene-edited products as genetically modified organisms
(GMOs), subjecting them to the same stringent restrictions that have
curbed GMO use in Europe.
This deadline was missed, as was a second one of end-March 2016, and
there is now no new timeline for a decision.
Both sides in the debate are worried.
Greenpeace wants the EU's GMO law to be fully applied to "new
breeding techniques" (NBT) like gene editing, because of potential
environmental and health impacts, and it fears Brussels is dithering
under pressure from Washington.
[to top of second column] |
"We are concerned that we would get products that are risky but
could arrive on the market without any risk assessment or labeling
or detection methods," said spokeswoman Franziska Achterberg.
She believes the EU has delayed regulation to pave the way for a
transatlantic trade deal, citing a document in which a U.S. official
warned that "different regulatory approaches between governments to
NBT classification would lead to potentially significant trade
disruptions".
A Commission spokesman denied the delays had anything to do with the
Transatlantic Trade and Investment Partnership trade pact talks, but
could not say when the EU would make a ruling.
Biotechnology companies, meanwhile, argue their gene-edited products
are "non-GMO", since they do not contain foreign DNA from a
different species.
"We fundamentally see gene editing as being very distinct from GMO,"
said Genus Chief Executive Karim Bitar. "It's a very precise cut and
there is no movement of genes from one species to another. That's a
major attraction."
FIND-AND-REPLACE FUNCTION
The argument is complex.
Unlike traditional GMOs, in which a gene is added from another
organism, gene-editing works like the find-and-replace function on a
word processor. It finds a gene and then makes changes by amending
or deleting it.
Proponents argue this makes it similar to conventional selective
breeding, which is freely allowed in the EU, since such mutations
within the same species can - and do - also occur naturally.
Rene Smulders, a plant breeder at Wageningen University in the
Netherlands, says the current uncertainty is affecting research. His
group had a grant application turned down last year because of
concerns about the legal situation.
He wants Europe to follow the lead of Canada, which decides on new
products based on their traits, not how those traits were produced.
"Europe's process-based legislation creates problems and is not
suitable for the future," Smulders said.
Cellectis CEO Andre Choulika, whose Calyxt unit has used older forms
of gene editing to improve potatoes, wheat and soybeans, thinks the
odds are 50:50 that gene-editing will end up being classified as GMO
in Europe.
"If Europe does that, I think they will probably send themselves
into the stone age of agricultural biotechnology," he said.
(Additional reporting by Barbara Lewis in Brussels; Editing by
Pravin Char)
[© 2016 Thomson Reuters. All rights
reserved.]
Copyright 2016 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |